Summary
Introduction
Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of cancer. The company's lead product candidate, PDX, is currently in Phase II/I for various cancers. This product candidate offers huge opportunity for the company in achieving commercial success in the near future.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company's pipeline includes only two clinical stage product candidates: PDX and RH1. PDX (pralatrexate) is the company's lead product, currently in Phase II development as monotherapy for treating Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Mesothelioma, Non-Hodgkin Lymphoma, and Non-Small-Cell Lung Cancer. RH1 is being developed for solid tumors (Phase I). The company did not recognize any revenues for the historical period 2002-2006. The company's only contributor to the sales growth out to 2010 will be revenues from its lead product candidate, PDX. Revenues from PDX are expected to increase from 4.2 million in 2009 increasing to $78.1 million in 2010. The product is expected to be launched in the US during 2009.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
